A New Technology for Identification of Genes Expressed in Hypoxia Conditions
Posted Jun 15 2010 5:00pm
Description of Invention: Low concentrations of oxygen (hypoxia) are a major pathophysiological condition conducive for angiogenesis, necessary for tumor growth and metastasis of cancer cells.
A new technology comprising of a vector DNA (pGL2-TK-HRE) that expresses the luciferase gene under the influence of a hypoxia inducible promoter sequence from the nitric oxide synthase gene has been used to transform various human tumor cell lines such as U251-HRE and PC3-HRE. These cells express little to none luciferase under normal oxygen levels, but stably express significantly higher levels under low oxygen levels.
The transformed cell lines can be used to screen and develop drugs and small molecules that inhibit angiogenesis, an attractive target for cancer therapy. The technology can also be used in gene therapy where the therapeutic gene is being expressed under a hypoxia inducible promoter.
Early detection of angiogenesis
Robust, stably express luciferase
Can be used in vivo
Development Status: Developed
Inventors: Giovanni Melillo (NCI)
Patent Status: Research Tool -- Patent protection is not being sought for this technology.
Licensing Status: Available for non-exclusive licensing.
Portfolios: Devices/Instrumentation Devices/Instrumentation - Research Tools and Materials Cancer Cancer - Research Materials In-vitro Data